All In Biotech

NDA 022198 · Apotex

Sancuso

Granisetron · Transdermal · Serotonin-3 Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Sep 12, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

124

32 Phase 3, 5 recruiting

FAERS reports

10,458

8,771 serious, 1,879 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2024.

SANCUSO ® is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration. SANCUSO is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. ( 1 )

Mechanism: Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1, 5-HT 1A , 5-HT 1B/C , 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SANCUSO · GRANISETRON 3.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Granisetron" as an intervention, any sponsor and status, largest first.

All 124 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,337
  • vomiting768
  • febrile neutropenia741
  • diarrhoea728
  • pyrexia664
  • death611
  • dyspnoea605
  • fatigue570
  • neutropenia492
  • anaemia491
  • off label use461
  • constipation404

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004129
2005106
200660
200774
200863
200954
2010129
2011250
2012626
2013392
2014446
2015481
2016829
2017686
2018859
2019943
2020871
2021834
2022831
2023528
2024461
2025495
2026310

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sancuso (Granisetron)

2024 spending

$6.6M

Beneficiaries

1,220

3,171 claims

Per beneficiary

$5,415

$669.52 per unit

View as table
YearSpending
2020$7,999,796
2021$7,590,638
2022$7,189,513
2023$6,806,991
2024$6,606,813

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 568 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.